By understanding and leveraging the mechanisms by which TSAs and TAAs are presented on MHC molecules and how activated CD8+ T cells mediate tumor cell destruction, cancer immunotherapy can be significantly advanced, offering a nuanced strategy to harness the immune system’s power against cancer. Here, CD8A is linked to cancer.